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Highlights 25 
 26 
1. Influenza vaccination coverage was 11.9% and 12.6% in the case and control 27 
groups respectively. 28 
2. The overall estimates of vaccine effectiveness were 46.9% (95% CI: -20.4%, 29 
76.6%) for the 2013-14 season and 5.0% (95% CI: -53.0%, 41.0%) for the 2014-30 
15 season. 31 
3. This study demonstrated the feasibility of routine assessment of influenza vaccine 32 
effectiveness using the test-negative design in Beijing. 33 
 34 
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ABSTRACT 37 
Background: Estimates of influenza vaccination effectiveness (VE) are valuable for 38 
populations where the vaccine has been promoted in order to support vaccination policy 39 
and to permit evaluation of vaccination strategies. Such studies would be important for 40 
China due to limited data available during seasons when the vaccine strains matched or 41 
mismatched the circulating viruses.  42 
Methods: We conducted a test-negative study in hospitals in Beijing. Patients admitted 43 
to five hospitals in the city were enrolled during the winter influenza seasons of 2013-14 44 
and 2014-15. Influenza virus infections were determined by PCR, and influenza 45 
vaccination records were extracted from a centralized electronic immunization registry. 46 
Influenza VE was estimated by logistic regression adjusting for age group, sex and 47 
chronic conditions, and matched by calendar week.  48 
Results: A total of 2368 inpatients were recruited during the study period with a 49 
vaccination coverage in the control group of 12.8%. The overall estimate of influenza VE 50 
was 46.9% (95% CI: -20.4%, 76.6%) for the 2013-14 season and 5.0% (95% CI: -53.0%, 51 
41.0%) for the 2014-15 season. Estimates of VE were relatively higher in children aged 52 
6-17 years than older persons across two influenza seasons while estimates of VE for 53 
both adults and elderly were relatively low. 54 
Conclusions: Our findings were consistent with expected influenza vaccination 55 
effectiveness in seasons when the vaccine matched or mismatched circulating viruses. 56 
Strategies to increase influenza vaccine coverage could provide a public health benefit.  57 
 58 
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INTRODUCTION 59 
Influenza vaccine effectiveness (VE) can vary from year to year, from location to 60 
location, and in persons of different ages, for a variety of reasons [1-5]. In populations 61 
where influenza vaccination is promoted, it can be valuable to have local estimates of VE 62 
to support policy and to permit evaluation of specific vaccination strategies [3, 6]. In 63 
recent years, a variant of the case-control study known as the test-negative design has 64 
become popular for routine estimation of influenza VE [7, 8].  65 
 66 
China is an upper middle income country in the northern hemisphere with a population of 67 
1.3 billion. The capital city Beijing in the northeast of China has a typical temperate 68 
climate with a population of 20 million. Sentinel surveillance data indicates that influenza 69 
viruses circulate every year in Beijing from late autumn through to spring of the next year. 70 
The municipal government of Beijing provided free influenza vaccination for adult 71 
residents ≥60y and subsidized influenza vaccination for elementary and high school 72 
students 6-17 years of age from 2007 to 2008, and provided free influenza vaccination to 73 
these two groups since 2009 [9]. However, few studies have evaluated influenza VE in 74 
Beijing or elsewhere in China [10]. In 2013-14, the influenza vaccine strains matched the 75 
circulating strains in China while most circulating A(H3N2) viruses in the 2014-15 76 
season were low reactors to the A/Texas/50/2012 (H3N2)-like virus used for the 77 
influenza vaccine in that season. As part of a global surveillance network with a unified 78 
core protocol [11, 12], we implemented a test-negative study based in hospitals to 79 
estimate VE in Beijing in the winter influenza seasons of 2013-14 and 2014-15. 80 
 81 
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METHODS 82 
Study setting and subjects 83 
Our study was carried out in 2 general hospitals in Beijing in the 2013-14 influenza 84 
season, namely Changping District Hospital and The First Hospital of Huairou. The study 85 
was expanded to 5 hospitals in the 2014-15 season by including 3 additional general 86 
hospitals, namely Daxing District Hospital, Miyun County Hospital and Liangxiang 87 
Hospital. Patients admitted to the department of respiratory medicine, pediatrics and 88 
geriatrics and the intensive care unit (ICU) in each hospital were screened for eligibility 89 
for the study.  90 
 91 
We aimed to include inpatients whose disease episode was potentially associated with 92 
infection of influenza virus in the study. Given the potential variation in clinical 93 
presentation, we adopted different inclusion criteria for patients younger than 5 years and 94 
those at age of 5 years and older. All patients 0-4y who were diagnosed any of the 95 
diseases listed in Appendix Table 1 met the diagnostic criterion for inclusion. For patients 96 
≥5y, the patient who was diagnosed as one of the diseases listed in Appendix Table 2 and 97 
at the same time met the influenza like-illness (ILI) definition was eligible for further 98 
screening. We adopted the ILI definition proposed by the European Centre for Diseases 99 
Control that an ILI patient should present any of four systemic symptoms (fever or 100 
feverishness, headache, myalgia or malaise) plus any of the three respiratory symptoms 101 
(cough, sore throat or shortness of breath). In our study, patients’ onset of ILI symptoms 102 
had to be within the 7 days prior to admission, and all recruited patients were admitted 103 
within the previous 24-48 hours. Only routine residents (living in the city for ≥6 months) 104 
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and non-institutionalized patients were eligible for this study. Patients who had been 105 
hospitalized in the previous 30 days were excluded.  106 
 107 
Two pharyngeal swabs were collected from each eligible patient and tested for influenza 108 
A (H1N1pdm09 and H3N2) and influenza B (B/Yamagata, B/Victoria) by RT-PCR. 109 
Demographic and related clinical information was obtained through face-to-face 110 
interview or review of clinical records, including age, sex, smoking habit of the patient 111 
(for adults) or parents (for children), pregnancy status, chronic conditions, influenza 112 
vaccination status in the current and the previous seasons.  113 
 114 
Ethical approval was obtained from the ethics committees in the participating hospitals. 115 
Participation was voluntary and informed verbal consent was obtained before enrollment. 116 
 117 
Definition of vaccination status 118 
Influenza vaccination status of recruited patients was determined by vaccination record 119 
registered in the Beijing Expanded Program on Immunization Information Management 120 
System. Vaccination was defined as patients who had received trivalent inactivated 121 
influenza vaccine (TIV) in the corresponding influenza season more than 2 weeks before 122 
hospitalization. Patients who had a contra-indication to influenza vaccination or received 123 
TIV less than 2 weeks before enrolment were excluded from the study. Vaccination 124 
schedules generally followed the recommendations from the World Health Organization 125 
[13]. Recruited patients who received at least one dose of influenza vaccine were 126 
identified as vaccinated. The 2013-14 influenza TIV was composed of 127 
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A/California/7/2009 (H1N1)pdm09-like virus, A/Victoria/361/2011 (H3N2)  and 128 
B/Massachusetts/2/2012-like virus. The 2014-15 influenza TIV was composed of 129 
A/California/7/2009 (H1N1)pdm09-like virus, A/Texas/50/2012 (H3N2)-like virus and 130 
B/Massachusetts/2/2012-like virus. 131 
 132 
Laboratory testing 133 
All swab samples were kept at -20°C after collection and shipped to a local influenza 134 
reference laboratory within 48 hours. RNA extraction was performed from 140μL 135 
sampling solution using QIAamp Viral RNA Mini Kit (Qiagen, Denmark) according to 136 
the manufacturer's instruction. The yield RNA was finally eluted using 50μL RNase-free 137 
water. For influenza A and B detection, primers were designed basing on the sequence 138 
supplied by Chinese National Influenza Center for the matrix protein. The tests were 139 
performed by rRT-PCR using AgPath-ID One-Step RT-PCR kit (Applied Biosystems, 140 
USA) and 7500 Fast Real-Time PCR System (Applied Biosystems) using 5μL of RNA 141 
according to manufacturer’s instruction and the WHO’s protocol [14]. For influenza A-142 
positive samples, a typing rRT-PCR assay was performed. For influenza B-positive 143 
samples, rRT-PCR was performed for the HA gene to distinguish B/Yamagata and 144 
B/Victoria lineages. 145 
 146 
Statistical analysis 147 
In our primary analysis, we restricted to two influenza seasons throughout the whole 148 
study period, which were defined as periods during which cases tested positive for 149 
influenza for two or more consecutive weeks. We used conditional logistic regression 150 
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models where the outcome was the specimen testing result, either positive or negative to 151 
a certain type/subtype of influenza viruses, and the covariate of interest was vaccination 152 
status, matching by calendar week of admission to account for variation in vaccination 153 
coverage over time. Potential confounders such as age group (6m-5y, 6-17y, 18-59y, 154 
≥60y), sex and chronic conditions were also included in the model. VE was defined as 155 
one minus the adjusted odds ratio. VE analysis was performed for influenza overall and 156 
by type/subtype, age and season. 157 
 158 
RESULTS 159 
Between December 9, 2013 and May 15, 2015, a total of 2368 patients presenting to the 160 
selected hospitals were recruited. Patients who were institutionalized (n=7), who were 161 
hospitalized within 30 days (n=15), who did not meet the ILI definition (n=45), and 162 
whose symptoms started more than 7 days before admission (n=61) were excluded. 163 
Among the remaining 2234 patients, children younger than 6 months were not eligible for 164 
influenza vaccination and thus excluded (n=33). Patients who had contradictions to 165 
vaccination were excluded (n=15), or vaccinated within 14 days of illness onset were 166 
excluded (n=7). Therefore 2179 patients meeting the inclusion criteria were enrolled 167 
during the study period and provided specimens for laboratory testing. The timeline of 168 
patient recruitment was shown in Figure 1. The winter 2013-14 influenza season started 169 
late in January 2014, and had influenza A(H1N1) (22.9%), A(H3N2) (22.9%) and B 170 
(54.2%) co-circulating throughout the season while the winter 2014-15 influenza season 171 
starting early in November 2014 was predominated by A(H3N2) (51.2%) at the 172 
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beginning of the season and followed by a predominance of influenza B (43.2%) from 173 
March to April (Figure 1B).  174 
 175 
We restricted VE analysis to the two influenza seasons occurring during our study period 176 
which were the time periods from 05 Jan 2014 to 19 Apr 2014 and from 16 Nov 2014 to 177 
09 May 2015 respectively. A total of 1725 of the 2179 patients were enrolled during the 178 
two seasons, including 353 who were test-positive for either influenza A or B virus, while 179 
1372 were test-negative for any type/subtype of influenza virus (Table 1). Test-positive 180 
cases were most frequently young children (n=131, 37.1%) and elderly (n=103, 29.2%), 181 
and the age distribution was similar in the control group.  182 
 183 
Influenza vaccination coverage was generally low, at 12.6% overall among the controls, 184 
and varied substantially by age in the control group: it was 2.4% in children aged 6 185 
months to 5 years, 31.2% in children 6-17y, 1.3% in adults 18-59y and 23.9% among 186 
adults ≥60y. The overall adjusted VE was 18.6% (95% confidence interval, CI: -22.0%, 187 
45.7%) against influenza A and B combined in the two influenza seasons (Table 2). 188 
Overall VE was modest (46.9%; 95% CI: -20.4%, 76.6%) for the 2013-14 season and low 189 
(5.0%; 95% CI: -53.0%, 41.0%) for the 2014-15 season. Influenza VE was estimated to 190 
be 59.5% (95% CI: -49.4%, 89.0%) for influenza A and 42.4% (95% CI: -59.7%, 79.2%) 191 
for influenza B in the 2013-14 season. However, the VE against influenza A(H3N2) and 192 
influenza B infection was 27.9% (95% CI: -41.5%, 63.3%) and -31.5% (95% CI: -153.9%, 193 
31.9%) in the 2014-15 season (Table 2).  194 
 195 
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Stratified estimates by season and age group are shown in Table 3. In season-specific and 196 
season-combined estimates of VE, we observed a declining trend of VE with increasing 197 
age. Since no children aged 6 months to 5 years testing positive for influenza in the 2013-198 
14 season had been vaccinated in our data, point VE estimates for this age group against 199 
all influenza virus infections was 100% for that season (Table 3). The overall VE 200 
estimate for children aged 6-17 years was 52.0% (95% CI: -9.0%, 78.9%), similar across 201 
two influenza seasons. However, VE estimates for both adults and elderly were relatively 202 
low, with estimates of -9.7% (95% CI: -1207.8%, 90.8%) and -33.2% (95% CI: -127.1%, 203 
21.9%) respectively (Table 3). 204 
 205 
DISCUSSION 206 
We used a hospital-based study to estimate influenza VE in Beijing in the 2013-14 and 207 
2014-15 winter influenza seasons. Since 2009, the Beijing municipal government has 208 
provided free influenza vaccination to school-age children 6-17y of age and adults ≥60y 209 
of age. Despite the free vaccination program, vaccine coverage was relatively low in the 210 
control groups of our study in those two age groups: 30% in children 6-17y and 20% in 211 
adults ≥60y of age. Vaccination coverage in the control group was generally lower than 212 
the coverage in the underlying population in Beijing, possibly because these newly 213 
admitted patients with ILI symptoms had relatively lower health awareness and therefore 214 
a lower probability to be vaccinated. The Beijing CDC recorded that around 1.5 million 215 
doses were administered each year in the city for the 2013-14 and 2014-15 seasons. 216 
Previously studies suggested that influenza vaccination covered around 70% of primary 217 
and middle school students (6-17y) and 40% of adults (≥60y) in Beijing [15, 16]. A 218 
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perceived lack of effectiveness of the vaccine and low risk of influenza infection might 219 
be the main barriers to increasing influenza vaccination coverage in Beijing [15]. Further 220 
evidence from test-negative studies, like the present study, demonstrating that influenza 221 
does present a substantial disease burden and that influenza vaccination is effective could 222 
increase the public’s willingness to receive free vaccination in Beijing. 223 
 224 
In the winter 2013-14 influenza season, we estimated an overall VE at 46.9% (95% CI: -225 
20.4%, 76.6%). This is comparable to other estimates of VE in the northern hemisphere 226 
and consistent with moderate VE [17, 18]. A study conducted in Greece where the 227 
influenza vaccination coverage was similar to Beijing estimated that the influenza 228 
vaccination was 34.5% (4.1%, 55.3%) effective against inpatient and outpatient 229 
infections [17]. Our estimate was lower than those reported from the United States (61%, 230 
95% CI: 52%, 68%) [19] and Canada (58.5%, 95% CI: 43.9%, 69.3%) [20], which could 231 
attribute to different circulating viruses in the two regions. In the 2013-14 season, 232 
influenza H1N1, H3N2 and B viruses were co-circulating in Beijing while in Canada and 233 
the United States it was predominated by H1N1 virus. Another potential explanation for 234 
poorer VE is the potential for waning immunity between administration of vaccines in 235 
October and November 2013 and the late peak of the 2013-14 influenza season in late 236 
January-March in Beijing 2014.  237 
 238 
However in the winter 2014-15 influenza season, we estimated an overall VE of 5.0% (95% 239 
CI: -53.0%, 41.0%) against hospitalization. The relatively low VE was also observed in 240 
other studies conducted in the Northern hemisphere. A study conducted in an early 241 
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season of influenza in the United States estimated a VE of 23% (8%, 36%) against 242 
medically attended acute respiratory infections [21]. Similarly, a mid-season study in the 243 
United Kingdom estimated a VE of 3.4% (−44.8%, 35.5%) against influenza overall and 244 
−2.3% (−56.2%, 33.0%) against H3N2 among patients presenting acute ILI symptoms for 245 
ambulatory care [22]. Interim VE estimates of the 2014-15 season in Canada were -16.8% 246 
(-4.9%, 8.3%) overall against hospitalizations among all ages, and -25.4% (-65.0%, 4.6%) 247 
for the elderly aged 65 years or above [20] while a similar study in Spain estimated a 248 
moderate influenza VE of 33% (6%, 53%) and 40% (13%, 59%) in all age groups and the 249 
elderly, respectively [23]. The lack of effectiveness of influenza vaccination might be 250 
attributable to the mismatch in the H3N2 component. In addition there was a late 251 
influenza B epidemic in Beijing in March and April 2015, and protective immunity from 252 
pre-winter vaccinations may have waned by this time. 253 
 254 
Our study has several limitations. First, similar to other observational studies, our study 255 
could suffer bias from unidentified potential confounders although the common 256 
confounding factors including age and underlying medical conditions had been adjusted 257 
for in the analysis to minimize biases of VE estimates. Second, our estimates of VEs may 258 
not be directly comparable with those from previous studies because we applied a list of 259 
pre-defined hospital admission diagnoses to indicate influenza-associated diseases that 260 
might differ from outcomes used in other studies. Third, using influenza-associated 261 
hospitalization as the outcome in our study might lead to under-detection of influenza 262 
viruses since the patients were likely to have a longer delay from symptom onset 263 
therefore less likely to be tested positive for influenza, while our data suggested that most 264 
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patients were admitted within 4 days after symptom onset. Nevertheless, we have shown 265 
in a review that estimates from hospital-based test-negative studies tend to provide 266 
similar estimates of VE compared to estimates from test-negative studies in outpatient 267 
settings [REF]. Lastly, our study might have less power to obtain a reliable estimate of 268 
VE in some age groups given the small number of vaccinees observed in these groups.  269 
 270 
In conclusion, our study provided estimates that were consistent with moderate influenza 271 
VE against laboratory-confirmed hospitalization in Beijing in the 2013-14 winter season, 272 
while the vaccine effectiveness was low in the 2014-15 season when vaccine components 273 
mismatched circulating virus strains. 274 
 275 
  276 
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FIGURE LEGENDS 
Figure 1. (A) Timeline of recruitment of patients testing positive or negative for influenza. 
(B) Timeline of recruitment of patients testing positive for influenza by type/subtype.
 20 
Table 1. Descriptive analysis of patients recruited during 2013-14 and 2014-15 winter 
influenza seasons in Beijing, China. 
Characteristics Test-positive 
(n=353) 
N (%) 
Test-negative 
(n=1372) 
N (%) 
p-value a 
Age group     
  6m-5y 131 (37.1%) 534 (38.9%) 0.020 
  6-17y 67 (19.0%) 173 (12.6%)  
  18-59y 52 (14.7%)  234 (17.1%)   
  ≥60y 103 (29.2%)  431 (31.4%)   
    
Male  212 (60.1%) 826 (60.2%) 1.000 
    
Chronic conditions b 111 (31.4%) 442 (32.2%) 0.831 
    
Receipt of TIV in the current season 42 (11.9%) 173 (12.6%) 0.787 
a p-values estimated by chi-squared tests. 
b  Chronic conditions included cardiovascular disease, chronic obstructive pulmonary 
disease, asthma, diabetes, immunodeficiency or organ transplant, renal impairment, 
rheumatologic disease, neuromuscular disease, cirrhosis or liver disease, neoplasm, 
autoimmune disease and hematological disease. 
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Table 2. Estimates of vaccine effectiveness of trivalent influenza vaccines against laboratory-confirmed influenza hospitalization 
during 2013-14 and 2014-15 winter influenza seasons.* 
 All Influenza Influenza A Influenza A(H3N2) Influenza B 
Overall 18.6% (-22.0%, 45.7%) 32.9% (-20.3%, 62.6%) 31.6% (-26.8%, 63.1%) 0.2% (-71.4%, 41.9%) 
     
Influenza season     
   2013-14 46.9% (-20.4%, 76.6%) 59.5% (-49.4%, 89%) 59.5% (-110%, 92.2%) 42.4% (-59.7%, 79.2%) 
   2014-15 5.0% (-53.0%, 41.0%) 27.1% (-43.1%, 62.9%) 27.9% (-41.5%, 63.3%) -31.5% (-153.9%, 31.9%) 
* From conditional logistic regression models adjusting for age group, sex and chronic conditions, and matched by calendar week. 
 22 
Table 3. Estimates of vaccine effectiveness of trivalent influenza vaccines against 
laboratory-confirmed influenza hospitalization in different age groups during 2013-14 
and 2014-15 winter influenza seasons. 
 Both seasons 2013/14 season 2014/15 season 
Overall 18.6% (-22.0%, 45.7%) 46.9% (-20.4%, 76.6%) 5.0% (-53.0%, 41.0%) 
    
Age group    
  6m-5y 81.2% (-52.3%, 97.7%) - a, b 70.6% (-163.2%, 96.7%) 
  6-17y 52.0% (-9.0%, 78.9%) 45.5% (-152.7%, 88.2%)a 56.1% (-17.5%, 83.6%) 
  18-59y -9.7% (-1207.8%, 90.8%) -- -13.0% (-1219.8%, 90.3%) 
  ≥60y -33.2% (-127.1%, 21.9%) 26.8% (-114.3%, 75.0%) -66.7% (-211.9%, 10.9%) 
Estimates of vaccine effectiveness from conditional logistic regression models adjusted 
for age group, sex, chronic conditions, and matched by calendar week, unless otherwise 
specified. 
a Estimated from conditional logistic regression models adjusting for age group, sex, and 
matching by calendar week. 
b The estimate was not provided because there were no vaccinated subjects in the group 
of cases testing positive for influenza, and a limited number of vaccinees in the 
corresponding control group during that season. 
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Appendix Table 1. Admission diagnoses potentially associated with influenza infections 
for patients less than 5 years old. 
Admission diagnoses ICD 10 Codes 
Acute upper or lower respiratory disease J00-J06, J20-J22 
Dyspnea, breathing anomaly, shortness of 
breath, tachypnea 
R06.0, R06, R06.9, R06.3, R06.00, R06.09, R06.83, 
R06.02, R06.82, R06.2, R06.89 
Asthma J45.2-J45.22, J45.9-J45.998, J44-J44.9 
Pneumonia and influenza J09-J18 
Heart failure I50-I50.9; I51.4 
Myalgia M79.1 
Altered consciousness, convulsions, febrile 
convulsions 
R40.20, R40.4, R40.0, R40.1, R56.00, R56.01 
Fever or fever unknown origin or non-
specified 
R50, R50.9 
Cough R05 
Gastrointestinal manifestations A09.0; A09.9 
Sepsis, systemic inflammatory response 
syndrome 
R65.10, R65.11, R65.20, A41.9 
 
  
Appendix Table 2. Admission diagnoses potentially associated with influenza infections 
for patients 5 years or older. 
Admission diagnoses ICD 10 Codes 
Acute respiratory infection  J00-J06, J20-J22, H66.90 
Acute myocardial infarction or acute 
coronary syndrome 
I20-I25.9 
Asthma  J45.2-J45.22, J45.9-J45.998, J44-J44.9 
Heart failure  I50-I50.9; I51.4 
Pneumonia and influenza  J09-J18 
Chronic Pulmonary Obstructive disease  J40-J44.9 
Myalgia  M79.1 
Malaise R53.81 
Metabolic failure (diabetic coma, renal 
dysfunction, acid-base disturbances, 
      
E11.9, E10.9, E11.65, E10.65, E10.11, E11.01, 
E10.641, E11.641, E10.69, E11.00, E10.10, E11.69, 
       
       
       
    
Altered consciousness, convulsions, febrile-
convulsions  
R40.20, R40.4, R40.0, R40.1, R56.00, R56.01 
Dyspnea/respiratory abnormality  R06.0, R06-R06.9 
Respiratory abnormality  R06.9 
Shortness of breath  R06.02 
Other respiratory abnormalities R06.3, R06.00, R06.09, R06.83 
Respiratory symptoms/chest symptoms  R06.89 
Fever or fever unknown origin or non-
specified 
R50, R50.9 
Cough R05 
Sepsis, Systemic inflammatory response 
syndrome 
R65.10, R65.11, R65.20, A41.9 
 
